ClinicalTrials.Veeva

Menu
D

DCOL Center for Clinical Research | Longview, TX

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Emtricitabine
Tenofovir Alafenamide
TAF
TDF
Islatravir
ISL
FTC
Rilpivirine
Tenofovir Disoproxil Fumarate
Bictegravir

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 75 total trials

A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)

The purpose of this study is to evaluate the safety and tolerability of DOR/ISL in adult participants with HIV-1 who had been previously treated with...

Active, not recruiting
HIV Infection
Drug: DOR/ISL

Human immuno-deficiency virus (HIV) is the virus that causes Acquired Immuno-Deficiency Syndrome (AIDS). HIV disease is considered to be a chronic di...

Enrolling
Human Immuno-deficiency Virus (HIV) Disease
Drug: Placebo for Budigalimab
Drug: Budigalimab

The purpose of this study is to learn about the safety and immune effects of a new pneumococcal vaccine in infants. The immune response is how the bo...

Enrolling
Pneumococcal Disease
Biological: PG4
Biological: 20-valent pneumococcal conjugate vaccine (20vPnC)

The primary objectives of this study are to evaluate the safety and tolerability of a switch to Doravirine/Islatravir (DOR/ISL) compared with continu...

Active, not recruiting
HIV-1 Infection
Drug: DOR/ISL
Drug: ART

The primary objectives of this study are to evaluate the antiretroviral activity of a switch to Doravirine/Islatravir (DOR/ISL) compared with continu...

Active, not recruiting
HIV-1 Infection
Drug: BIC/FTC/TAF
Drug: DOR/ISL
Locations recently updated

This is a randomized, active-controlled, double-blind clinical study designed to evaluate the antiretroviral activity, safety, and tolerability of do...

Enrolling
HIV-1 Infection
Drug: BIC/FTC/TAF
Drug: Placebo to DOR/ISL

This is a randomized, controlled, double-blind, study to evaluate the safety and tolerability of islatravir (ISL) + ulonivirine based on review of th...

Active, not recruiting
HIV-1 Infection
Drug: Islatravir
Drug: Placebo to Ulonivirine

Primary Objective:To evaluate the efficacy of dupilumab administered every 2 weeks in patients with moderate or severe Chronic Obstructive Pulmonary...

Active, not recruiting
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Inhaled Long-Acting Muscarinic Antagonist
Locations recently updated

The goal of this clinical study is to learn more about the experimental drugs GS-1720 and GS-4182; to compare the combination of GS-1720 and GS-4182...

Enrolling
HIV-1-Infection
Drug: Placebo to Match BVY
Drug: Placebo to Match GS1720/GS-4182 FDC

The primary objective of this study is to evaluate the antiviral activity of lenacapavir (formerly GS-6207) administered as an add-on to a failing re...

Active, not recruiting
HIV-1-infection
Drug: Optimized Background Regimen (OBR)
Drug: Oral Lenacapavir Placebo

This study will evaluate the safety and efficacy of a switch to MK-8591A (a fixed dose combination of doravirine and islatravir) in human immunodefic...

Active, not recruiting
HIV Infection
Drug: Placebo to BIC/FTC/TAF
Drug: Placebo to FDC DOR/ISL

Trial sponsors

Gilead Sciences logo
Merck Sharp & Dohme (MSD) logo
Mead Johnson Nutrition logo
Abbott logo
Pfizer logo
S
Bausch Health logo
B
AbbVie logo
A

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems